Source comparison
CJC-1295 no DAC & Ipamorelin: Protocol Comparison
Researchers designing studies around growth hormone secretagogues face a decision: single-agent protocols, combination protocols, or comparisons against other peptide classes. The table below maps the practical differences. CJC-1295 no DAC (solo) 1–3x daily 30
This comparison does not assign a generated winner or score.
- Researchers designing studies around growth hormone secretagogues face a decision: single-agent protocols, combination protocols, or comparisons against other peptide classes. The table below maps the practical differences.
- CJC-1295 no DAC (solo)
- 1–3x daily
- 30–60 min post-dose
- GHRH receptor sensitivity studies, amplitude measurement
- 4–6 hours
- Excellent for isolating GHRH pathway but lacks ghrelin receptor data
- Ipamorelin (solo)
- 2–3x daily
- 20–45 min post-dose
- Ghrelin receptor studies, appetite modulation research
- 6–8 hours
- More selective than GHRP-6 (no cortisol/prolactin spike) but lower peak GH than combinations
- CJC-1295 no DAC + Ipamorelin (1:1)
- 30–90 min post-dose
- Dual-pathway secretion, body composition, metabolic studies
- Gold standard for physiological pulsatile GH research. Synergistic release patterns
- Sermorelin (comparison)
- 1x daily (typically pre-sleep)
- Long-term GHRH exposure studies
- 12–16 hours
- Longer peptide chain (29 amino acids vs 30 for CJC-1295); less stable in storage
- GHRP-2 (comparison)
- 20–40 min post-dose
- Aggressive GH release studies
- Higher peak GH than Ipamorelin but elevates cortisol/prolactin. Less clean data
- Hexarelin (comparison)
- 1–2x daily
- 15–30 min post-dose
- Maximal GH secretion studies, cardioprotection research
- 8–12 hours
- Most potent GHRP but rapid desensitisation after 14–21 days. Poor choice for chronic studies
- The 1:1 combination of CJC-1295 no DAC and Ipamorelin dominates current research for three reasons: synergistic GH release (3–4× higher than predicted additive effect), clean side-effect profile (no cortisol or prolactin elevation unlike GHRP-2 or GHRP-6), and pharmacokinetic compatibility (overlapping active windows without excessive accumulation). Real Peptides' CJC1295 Ipamorelin 5MG 5MG combination formulation simplifies procurement and ensures matched purity between compounds. Critical for reproducible research.